Medical Director of Lung Innovations Network and The Lung Center at Penn Highlands Healthcare, Sandeep Bansal, M.D., Joins bioAffinity Technologies’ Medical and Scientific Advisory Board and Incorporates CyPath® Lung into Medical Practice
- None.
- None.
Lung Innovations Network, a patient-centered practice that offers comprehensive lung care to over 10,000 patients in central and western
“As a clinician, I see hundreds of patients a year who can directly benefit from CyPath® Lung, bioAffinity’s patient-friendly, noninvasive test for lung cancer. As a researcher, I am excited about the Company’s ongoing studies to advance CyPath® Lung, as well as noninvasive tests for other lung diseases,” Dr. Bansal said. “I look forward to contributing to bioAffinity’s innovative approach to lung health by working with the Company’s science team and the esteemed physicians and researchers who sit on its advisory board.”
Dr. Bansal has extensive experience in minimally invasive pulmonary procedures including navigational and robotic bronchoscopy, endobronchial ultrasound and chest sonography, argon plasma coagulation, cryotherapy, airway stenting, bronchoscopic lung volume reduction and indwelling pleural catheters. A principal investigator of multiple clinical research trials and a journal reviewer for several medical journals, he has been instrumental in developing a comprehensive lung center that allows a rapid assessment and management of healthcare needs based on the population characteristics and available resources. The model has been very successful in bringing advanced pulmonary services, including the latest technology and population health services, including a robust lung cancer screening program, to support the region’s clinical needs.
“Dr. Bansal is a highly regarded clinician and researcher who will be a strong addition to our stellar Medical and Scientific Advisory Board. His demonstrated commitment to saving lives and improving patients’ quality of life through innovative therapies and his prodigious research are truly impressive,” bioAffinity Technologies President and CEO Maria Zannes said. “The caliber of our Advisory Board is a testament to the commitment each physician has placed on bringing breakthrough technology to market in the battle against lung cancer and other diseases of the lung.”
About CyPath® Lung
CyPath® Lung uses advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath® Lung incorporates a fluorescent porphyrin, TCPP, that is preferentially taken up by cancer and cancer-related cells. Clinical study results demonstrated that CyPath® Lung had
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatment. The Company’s first product, CyPath® Lung, is a noninvasive test for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies, Inc. For more information, visit www.bioaffinitytech.com and follow us on LinkedIn, Facebook and X (Twitter).
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding Dr. Bansal’s contributions to the Company . These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, Dr. Bansal’s ability to make contributions to the Company and the other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240206573251/en/
Lung Innovations Network
Dawn Jeannerat
Vice President of Operations
djeannerat@lunginnovations.com
bioAffinity Technologies
Julie Anne Overton
Director of Communications
jao@bioaffinitytech.com
Investor Relations
Dave Gentry
RedChip Companies Inc.
1-800-RED-CHIP (733-2447)
Or 407-491-4498
BIAF@redchip.com
Source: bioAffinity Technologies, Inc.
FAQ
What is the ticker symbol for bioAffinity Technologies, Inc.?
What is the focus of bioAffinity Technologies, Inc.?
Who has recently joined bioAffinity Technologies, Inc.?
